title: Assessing commercial opportunities for autologous and allogeneic cell-based products.
abstract: The two primary cell sources used to produce cell-based therapies are autologous (self-derived) and allogeneic (derived from a donor). This analysis attempts to compare and contrast the two approaches in order to understand whether there is an emerging preference in the market. While the current clinical trials underway are slightly biased to autologous approaches, it is clear that both cell-based approaches are being aggressively pursued. This analysis also breaks down the commercial advantages of each cell-based approach, comparing both cost of goods and the ideal indication type for each. While allogeneic therapies have considerable advantages over autologous therapies, they do have a distinct disadvantage regarding potential immunogenicity. The introduction of the hybrid autologous business model provides the ability for autologous-based therapies to mitigate some of the advantages that allogeneic cell-based therapies enjoy, including cost of goods. Finally, two case studies are presented that demonstrate that there is sufficient space for both autologous and allogeneic cell-based therapies within a single disease area.
authors.affiliation: Pfizer Worldwide R&D, The Portway Building, Granta Park, Great Abington, Cambridge CB21 6GS, UK. devyn.m.smith@pfizer.com
authors.forename: Devyn M
authors.initials: DM
authors.lastname: Smith
mesh_terms: D002986:Clinical Trials as Topic / Q000191:economics; D003132:Commerce; D006801:Humans; D018803:Models, Economic; D033581:Stem Cell Transplantation / Q000191:economics*; D014182:Transplantation, Autologous / Q000191:economics; D014184:Transplantation, Homologous / Q000191:economics